An open treatment trial of venlafaxine for elderly patients with dysthymic disorder.

Treatment response and side effects of venlafaxine were evaluated in an open-label trial of elderly outpatients with dysthymic disorder (DD). Patients received flexible dose (up to 300 mg/d) venlafaxine (Effexor XR) for 12 weeks. Of 23 study patients, 18 completed the trial. Fourteen (60.9%) were responders in intent-to-treat analyses with the last observation carried forward, and 77.8% were responders in completer analyses. Nearly half the sample (47.8%) met criteria for remission. In the intent-to-treat sample, increased severity of depression at baseline was associated with superior response, and the presence of cardiovascular disease was associated with poorer response. Venlafaxine open-label treatment was associated with fairly high response rates and generally good tolerability in elderly patients with DD. These results indicate that in elderly patients with DD, placebo-controlled trials of a dual reuptake inhibitor such as venlafaxine would be needed to assess its efficacy or to compare its efficacy to that of other antidepressants.
AuthorsD P Devanand, Nicole Juszczak, Mitchell S Nobler, Nancy Turret, Linda Fitzsimons, Harold A Sackeim, Steven P Roose
JournalJournal of geriatric psychiatry and neurology (J Geriatr Psychiatry Neurol) Vol. 17 Issue 4 Pg. 219-24 (Dec 2004) ISSN: 0891-9887 [Print] Canada
PMID15533993 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cyclohexanols
  • Serotonin Uptake Inhibitors
  • Venlafaxine Hydrochloride
  • Aged
  • Cyclohexanols (administration & dosage, therapeutic use)
  • Diagnostic and Statistical Manual of Mental Disorders
  • Drug Administration Schedule
  • Dysthymic Disorder (diagnosis, drug therapy)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Serotonin Uptake Inhibitors (administration & dosage, therapeutic use)
  • Venlafaxine Hydrochloride

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: